Ticker Details
Ovid Therapeutics Inc. Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
IPO Date:	May 10, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$104.68M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.40%
Avg Daily Range (30 D):	$0.06 | 3.65%
Avg Daily Range (90 D):	$0.06 | 4.11%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	1.28M
Avg Daily Volume (90 D):	1.51M

Trade Size
Avg Trade Size (Sh.):	223
Avg Trade Size (Sh.) (30 D):	283
Avg Trade Size (Sh.) (90 D):	331

Institutional Trades
Total Institutional Trades:	114
Avg Institutional Trade:	$2.12M
Avg Institutional Trade (30 D):	$.6M
Avg Institutional Trade (90 D):	$.6M
Avg Institutional Trade Volume:	.56M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.45M
Avg Closing Trade (30 D):	$1.44M
Avg Closing Trade (90 D):	$1.44M
Avg Closing Volume:	821.93K

News

Nov 12, 2025 @ 12:00 PM Ovid Therapeutics Announces Planned Leadership Suc... Source: Ovid Therapeutics

Feb 27, 2025 @ 1:00 PM Ovid Therapeutics to Present at the TD Cowen 45th ... Source: N/A

Feb 20, 2025 @ 6:00 PM Epilepsy Market Assessment in the 7MM by 2034 ââ‚... Source: Delveinsight

Feb 5, 2025 @ 1:00 PM Ovid Therapeutics to Present at the Oppenheimer 35... Source: N/A

Jul 1, 2024 @ 12:00 PM Ovid Therapeutics and Graviton Bioscience Announce... Source: Ovid Therapeutics Inc.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS
Diluted EPS
Revenue	$6.61M	$.13M
Gross Profit
Net Income / Loss	$-36.33M	$-12.16M	$-4.68M
Operating Income / Loss	$-40.87M	$-12.52M
Cost of Revenue
Net Cash Flow	$5.59M
PE Ratio